COVID-19 Vaccine Update (Green, 12/16/2020)

Okay, so often enough when I am writing these summaries, I cannot do the speaker justice with my summary; this time the ante is upped. If you haven't gotten a chance to listen to Dr. Gary Green's Grand Rounds from 12/16/2020 and you are wondering about the science behind these vaccines, please watch it. Here is the link: https://www.youtube.com/watch?v=cBTnlrcHaKU&feature=youtu.be

For those of you who prefer written word, here are my summary points:

COVID-19 is raging in the California right now, over 60,000 cases reported yesterday. In SoCo, we had a reported 606 cases yesterday-- that is more than triple our previous high from last week. Some experts have called this "the third wave", but Dr. Green referred to our current California and local surge as our "second wave" because California didn't see a surge back in April/May when NYC did (see image below).


Historical context
Dr. Green encouraged us to reflect upon the tremendous historical impact of this pandemic, comparing peak daily death rates to Pearl Harbor, D-day and 9-11, which were each ONE day events. We have had many days and days of equivalent number of deaths during 2020. 
Looking at the 1918 flu epidemic, it's important to note that the initial pandemic included THREE waves (spring, fall, winter) that spanned the first 1 1/2 years of the pandemic but that the pandemic flu strain (in the absence of a vaccine)  wreaked havoc for several years after the initial 3 waves (1921, 22, and 23, see image). Hopefully vaccination will save us from such a long tail!

Multi-pronged strategy to control COVID-19 in our communities
We should remember that management of this pandemic has several key public health pillars, which remain important. The vaccine is additive to the important strategies already being implemented. These include:
  • Full PPE for healthcare workers with care of COVID patients and PUIs
  • Surgical masks at all times
  • Frequent hand washing
  • Social distancing when possible (6 feet)
  • Break room modification to avoid crowding
  • Avoid carpooling or socializing outside of work/family
  • Avoid social mixing (keep your bubble small)
  • Vaccination
Vaccination
On 12/11/2020, the Emergency Use Authorization was approved by the FDA for the Pfizer mRNA vaccine for COVID in persons >16 years and older. On 12/17, the advisory committee is meeting to review the mRNA vaccine from Moderna for persons >18 and older. It is expected to be approved also under EUA. 

Vaccines in the pipeline
Experts agree that we need multiple different vaccines to be able to fill the world's supply. There are currently 160+ vaccines in preclinical trials, 1 (Pfizer) approved last week for EUA and a second likely to be approved within days, and . To track these vaccines, you can follow their progress at the NY Times vaccine tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html


What do we want a vaccine to do?
  • prevent infection
  • prevent illness
  • prevent severity/fatality if you get sick
  • prevent transmission
What is this new mRNA technology and should I trust it? It all happened so fast. . .

First of all, scientists have been working on this mRNA technology for many years, decades in fact. Both the Pfizer and the Moderna vaccine use the mRNA of the COVID-19 spike protein to provoke an immune response. You can NOT get COVID from the vaccine. While you are right, this was quite quick, it's not out of nowhere. Over the last two decades, there have been rapid improvements in vaccine creation: the SARS vaccine was created in 20 months (2003), H1N1 (2009) in just 9 months (2009), and Zika in 3.25 months (2013). The science is sound. 

How effective is the mRNA vaccine?
Both mRNA vaccines (Pfizer and Moderna) are designed to require two doses. It appears that after two doses, both vaccines are 94-95% effective. This is MUCH better than anyone could have hoped for; in fact, several months ago, the FDA said that it wouldn't consider a vaccine to be approved unless it was at least 50% effective. This is so much better than that!

See the data below from the Pfizer study in the image below. In this study of 44K people, the vaccine demonstrated 52.4% efficacy after first dose (there were 39 cases of COVID in the vaccine group and 82 in the placebo group), but 95% after the second dose, given 21 days later (162 cases in placebo group, 8 cases in the vaccinated group, none severe).

What about the vaccine side effects?
Yes, the Pfizer vaccine is a reactogenic vaccine (think Tetanus shot or Shingrix). Many folks will have a sore arm (84%). More than half will get fatigue (62.9%) and headache (55.1%), and a significant amount will get muscle aches (38.3%), joint pains (31.9%), chills (23.6%), and fever (14.2%).   The Moderna vaccine has very similar side effect profile (e.g. 90% injection site reactions and 68% fatigue, and 15% fever). Expect more side effects after the second dose than the first.

Also of note are a few unique events, including lymphadenopathy and a higher than expected rate of Bell's Palsy. Also reported in post-marketing (not during the study) are 3 events in UK and 2 in the US of anaphylactic-like reactions, almost all of which occurred in people with a history of anaphylaxis. This is being watched closely. The CDC recommends patients be observed for 15 minutes after injection to be sure they don't have such a reaction (30 minutes if you have hx of anaphylaxis). They are recommending if you have had anaphylaxis specifically to any vaccine, you should not get it at this time.

What about pregnancy and lactation?
Pregnancy and lactation were both excluded from both Pfizer and Moderna studies. However, in both studies, there were incidental pregnancies and no demonstrated adverse outcomes. The FDA says pregnancy is NOT a contraindication. ACOG and SMFM take it a step further: both recommend the vaccine in the 2nd and 3d trimester.

Are there any contraindications?
People who have had COVID-19 are recommended to get the vaccine, 90 days after infection. But, at this point, there are no known clinical contraindications. . As it is NOT a live vaccine, immunocompromised folks are safe getting it, there is no evidence of neurological side effects, folks with GBS are recommended. 

How do we get to herd immunity?
Dr. Green walked us through the notion of the basic reproduction number of a virus (R0, thought to be around 2.5-3.5 for COVID-19 under natural circumstances). He explained how both the R0 of COVID-19 AND the specific vaccine efficacy ultimately determine our ability to achieve herd immunity. 

Remember that herd immunity occurs when a large portion of a community (the herd) becomes immune to a disease, making the spread of disease from person to person unlikely. As a result the whole community is protected (not just those who are immune). For the math geeks out there, refer to this paper from the Lancet. Basically we need to get 63-75% of the population vaccinated with either of these current 94% effective vaccines to get to herd immunity. 


Final take homes:
1) Get vaccinated! 2 doses, either vaccine
2) Because this is being licensed under the emergency use authorization (EUA), vaccine is highly recommended but not mandated for all persons >16 years old
3) Moderna vaccine is likely to be approved and distributed in a matter of days (doesn't need to be kept at sub-zero temperatures, similar side effect profile, similar efficacy, may ultimately be easier to distribute to community). 
4) Getting vaccinated does NOT mean we can abandon the rest of our public health pillars. We will still continue to need to use PPE in the healthcare setting, wear masks, maintain social distancing, keep our social bubbles small, and wash our hands like our lives depend on it.

Therapeutic Neonatal Hypothermia (Spicher, 12/9.2

 A HUGE thank you to Dr. Allison Spicher, who gave an excellent presentation of the assessment of neonates at birth and indications for Therapeutic Neonatal Hypothermia. Cooling compromised babies became standard practice right around the time I graduated from residency-- I really needed this review and update. 

Here are my notes. . .

Therapeutic Neonatal Cooling is a clinical treatment that involves moderately reducing a baby's body temperature to slow disease progression and to improve health. In this case, the goal is to prevent neurological disability in at-risk neonates. Typically a baby is cooled to a core temperature of 33.5 degrees Celsius (92.3 degrees F) for 72 hours. 


Benefits of cooling have been demonstrated repeatedly:

2013 Cochrane Review. 1505 infants, 11 RCTs
  • 25% overall relative risk reduction of death or major neurodevelopmental disability at 18-24 months (32% moderate encephalopathy, 17% severe encephalopathy) 
  • The NNT to prevent 1 infant from dying or, becoming disabled is 6 for moderate, 7 for severe

Indications for cooling:

  • Biochemical (Arterial Blood Gas pH<7 or Base Deficit >16)
  • Neurological (moderate to severe encephalopathy)
AND
  • >36 weeks of gestational age
  • <6 hours of age
The Anatomy of a placenta:
  • There are TWO small umbilical arteries, which take waste and carbon dioxide AWAY from the baby (pictured in blue on image below)
  • There is ONE large umbilical vein that delivers oxygen and nutrients TO the baby (pictured in red on image below)
Of note, umbilical cord blood gases should be drawn as soon as possible from a preserved segment of the cord (taken at time of birth). Both arterial and venous samples are drawn in order to be able to compare them and be sure you are analyzing the correct information
Studies show that most accurate results come from samples drawn within 20 minutes of birth
Also, of note, Arterial pH and PO2 should always be lower than venous pH and PO2 (and pH should be at least 0.03 lower, or suspect that you have two venous samples)
Errors with umbilical cord blood gases are not uncommon. Reasons for this include:
  • mislabeled/mixed up (can tell this by PO2 in arterial sample >> PO2 in venous sample)
  • two venous samples (pH should be greater than 0.03 difference)
  • air bubbles (tend to increase PO2 and lower PCO2)
  • time to collection (PO2 and PCO2 have no major changes within 60 minutes, but BD can increase after 20 minutes-- if unable to draw quickly, put segment on ice)
What is neonatal encephalopathy?
Neonatal encephalopathy can be challenging to diagnose and there is NOT a standardized definition. ACOG and AAP definition appears in the figure here:
Sarnat Staging System
All compromised babies should be scored using the Sarnat Staging System, developed in 1976.  It uses 6 clinical findings to classify severity (1-mild, 2-moderate, 3-severe)

Exclusion Criteria for Cooling at SSRRH
  • severe IUGR (<1800gm)
  • need for ECMO
  • severe coagulopathy with active bleeding
  • severe hemodynamic compromise
  • severe chromosomal, major congenital anomalies/disorders known to cause severe neurodevelopmental impairment
What kind of follow-up do this babies  get?
Babies who receive therapeutic hypothermia are seen in a high risk infant follow-up clinic at Sutter Santa Rosa at 6 months, 1 year, 2 years for developmental assessment. They also have follow-up with Pediatrics Neurology at CPMC. For more information, contact the coordinator of the high risk infant follow-up clinic: Anne E Parker, parkerae@sutterhealth.org

Trauma Exposure Response
Dr. Spicher ended her Grand Rounds presentation on a reflection on our response to trauma in the work we do. As she reflected during per presentation, participating in the care of an acute ill neonate is always traumatizing, and healthcare providers carry this trauma with us through our professional work and our personal lives.  Dr. Spicher recommended a book for those of you who are interested in delving into this topic and do the work to care for ourselves while caring for others.




RESOURCES:

Good resource for videos of physical exam for neonates with suspected encephalopathy: https://wusthoff.people.stanford.edu/neurologic-exam-neonates-suspected-encephalopathy-0

 Another resource is the FN3 (Florida Neonatological Neurological Network)
 http://hopefn3.org/members/protocols-and-guidelines/

Fetal Acid Base Status and umbilical cord sampling: https://www.mc.vanderbilt.edu/dept/obgyn/High_Risk_Conference/2013/Fetal%20Acid%20Base%20Status%20and%20Umbilical%20Cord%20Sampling-%20D.%20Acker.pdf

Cochrane Review of cooling: https://www.cochrane.org/CD003311/NEONATAL_cooling-for-newborns-with-hypoxic-ischaemic-encephalopathy








The Other "O" in Prescription Safety: Benz-O-diazepines (Threlfall, 12/2/2020)

Many thanks to psychiatrist Dr. Alex Threlfall for a compelling and important Grand Rounds this week on Benzodiazepine Use Disorder, or as he aptly put it, The Other "O" in Prescription Safety. This is SUCH an important topic and one that hasn't gotten enough of our attention over the last decade of opiate deprescribing. 

TAKE HOME POINT #1 Do NOT prescribe benzodiazepines. . .unless they are absolutely indicated. BZD role is limited, but there are some reasonable indications.

Reasonable indications for a short course of BZD are very limited. They include: 

  1. crisis situations
  2. acute bipolar mania (for induction of sleep)
  3. alcohol withdrawal (maybe. . .but consider BZD sparing options) 
  4. seizure disorders 
  5. procedures 
  6. some phobias (e.g. VERY limited amount for airplane, not to be combined with alcohol)

And if you do prescribe in any of the above scenarios:

  • Use the lowest effective dose
  • Avoid alprazolam
  • Restrict prescription to 2 weeks or less

Here is why:

  • After opioids, BZD are the drug class most commonly involved in intentional and unintentional pharmaceutical overdoses (29.4%)
  • The overdose death rate involving BZD from 2011 to 2014 has increased five fold with opioids involved in 75% of these deaths (see diagram below from the NIH):

Dr. Threlfall outlined for us SIX areas of high risk with regards to BZD prescription

  1. Mental health conditions associated with trauma (e.g. PTSD but also depression, anxiety, etc)
  2. History of substance use disorder
  3. Elderly
  4. Compromised pulmonary function (e.g. moderate to severe COPD)
  5. Women of child-bearing age
  6. Patients suffering from chronic pain with or w/o opioid use

TAKE HOME POINT #2: Don't start any new prescriptions for BZD in anyone who meets any of the above criteria. 

Trauma is an integral part of our daily interaction with patients.
  • physical or sexual abuse in childhood is reported by 20-50% of adults
  • up to 70% of patients with depression, IBS, chronic pain, substance use report childhood physical or sexual abuse
There is NO evidence supporting the use of benzodiazepines in trauma. 
  • not only are they ineffective, but they can lead to adverse outcomes in PTSD
    • reducing efficacy of therapy
    • prone to misuse and development of substance use disorder
    • dangerous with substance use disorder often associated with trauma (ETOH, opioids)
Physical and psychological dependence can establish itself rapidly, especially in vulnerable patient populations. 
We should be very cautious and thoughtful about our use of BZD in the elderly-- in fact, we should really NOT be prescribing benzodiazepines
  • in one study of elderly patients on BZD , fewer than 1% had been referred for psychotherapy despite carrying mental health diagnoses
  • anxiety and insomnia are commonly diagnoses 
  • there has been a 32% increase in continuing BZD prescriptions for elderly
BZD are associated with significant risks in the elderly
  • falls
  • hip fractures
  • sedation
  • cognitive impairment
  • motor vehicle crashes
Department of Veteran Affairs- Benzodiazepine Educational Guide

Anxiety and insomnia are the two principal indications for prescribing benzodiazepines, but BZD are NOT first line for either of these conditions. 

Studies show that BZD are not effective for generalized anxiety disorder (GAD)
  • 1st line: SSRI/SNRI +/- psychotherapy, buspirone
  • 2nd line:  gabapentin, pregabalin, propranolol, clonidine*, amitriptyline/nortriptyline*, hydroxyzine, diphenhydramine (*indicates not for elderly)
  • BZD are THIRD line for anxiety.
All professional organizations recommend against the use of benzodiazepines as first line therapy for insomnia

All recommend Cognitive Behavioral Therapy for Insomnia (CBTi) as first line
2nd line: melatonin, prazosin (if nightmare), trazodone>mirtazapine (at lower doses more effective for insomnia)>doxepin>amitriptyline/nortriptyline
3rd line: hydroxyzine/diphenhydramine, non-benzo (zolpidem/Ambien)> ezoplicone>zalaplon
BZD are FOURTH line for insomnia

If you ARE going to start a bzd:
  • should be VERY rare
  • only for short term relief of acute anxiety/panic (2-4 weeks) and chronic insomnia (1-2 weeks)
  • get psychiatry consult to review chart
  • have explicit conversation with patient that this is very short term, discuss exit strategies
  • review risks with patient, including risk of dependence
  • only one prescriber, urine tox screen, CURES, contract
  • Recommended meds: lorazepam 2mg TDD, clonazepam 1.5mg TDD, diazepam 15mg TDD, temazepam 30mg TDD
Dr. Threlfall didn't have time to to talk about the specifics of BZD tapering, but please contact me if you want those slides.

He ended on the notion that direct patient education works. The 2014 EMPOWER study by Tennenbaum et al showed that simply informing patients of the risks of BZD motivates a significant percentage to initiate conversations about taper with their doctors AND successfully discontinue BZDs at 6 months (so cool!)

TAKE HOME POINT #3: So, yes, final take home point: talk to your patients about the risks of BZD. Maybe they will even be able to convince YOU they want to stop them. 






Vaping: Medicine or Menace (Ling, 11/13/2024)

 A recording of this presentation is available HERE . *** This was a mind-blowing and practice-changing Grand Rounds this week -- so much to...